Daraxonrasib a first-in-class RAS (ON) multi-selective tri-complex inhibitor for oncogenic RAS-driven malignancies

Nirumal Rakkesh1*, Priya Arumugam2, Ragul Ezhumalai2

1Head of Department, Department of Clinical Pharmacology, Apollo Specialty Hospital, Teynampet, Tamil Nadu

2Clinical Pharmacist, Department of Clinical Pharmacology, Apollo Specialty Hospital, Teynampet, Tamil Nadu

*Correspondence

Abstract

Daraxonrasib is an oral, noncovalent RAS (ON) multi-selective inhibitor that represents a novel approach to direct pharmacological inhibition of oncogenic RAS. The drug targets the active GTP-bound state of RAS through formation of a ternary complex involving daraxonrasib, cyclophilin A, and RAS (ON), thereby interfering with RAS- effector interactions and downstream signaling. In the phase 3 RASolute 302 trial, 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma were randomized to daraxonrasib or investigator’s-choice chemotherapy. In the overall population, median overall survival was 13.2 months versus 6.7 months and median progression-free survival was 7.2 months versus 3.6 months, respectively; the hazard ratios were 0.40 for overall survival and 0.49 for progression-free survival. Objective response rate was 30% versus 11%. On August 26, 2026, the U.S. FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy or for patients who are not candidates for multiagent systemic therapy. The recommended dose is 300 mg orally once daily until disease progression or unacceptable toxicity. Key safety concerns include dermatologic and soft-tissue toxicity, stomatitis/oral disorders, diarrhea, gastrointestinal perforation, interstitial lung disease/pneumonitis, and embryo-fetal toxicity. Daraxonrasib provides clinical validation of active-state, multi-selective RAS inhibition and establishes a new therapeutic paradigm for RAS-driven malignancies.

Keywords: Daraxonrasib; Rasonque; RMC-6236; RAS(ON); KRAS; Cyclophilin A; Tri-complex inhibitor; Pancreatic adenocarcinoma; Targeted therapy; Precision oncology.

Introduction

The RAS family of small GTPases- KRAS, NRAS, and HRAS-is a central regulator of cellular proliferation, differentiation, survival, migration, and metabolism. RAS functions as a molecular switch between an inactive GDP-bound state (RAS OFF) and an active GTP-bound state (RAS ON). Activating oncogenic alterations can sustain RAS signaling and drive tumor growth through pathways including RAF-MEK-ERK and PI3K-AKT-mTOR.Pancreatic ductal adenocarcinoma (PDAC) is particularly dependent on RAS biology, with oncogenic RAS mutations present in more than 90% of tumors. Historically, RAS was considered difficult to drug because of its high-affinity nucleotide binding and limited conventional binding pockets. Daraxonrasib introduces a distinct strategy: active-state RAS inhibition through a noncovalent CypA-mediated tri-complex mechanism.

Drug Profile

Table 1 summarizes key clinical and pharmacological characteristics.

Parameter Daraxonrasib
Generic name Daraxonrasib
Brand name Rasonque
Development code RMC-6236
Class RAS(ON) multi-selective inhibitor
Mechanism Noncovalent CypA-mediated tri-complex inhibition
Target Active GTP-bound RAS
Route Oral
Approved dose 300 mg once daily
FDA indication Metastatic pancreatic adenocarcinoma in adults after ≥1 prior systemic therapy or not candidates for multiagent systemic therapy
FDA approval date August 26, 2026
Key trial RASolute 302; NCT06625320

RAS Biology and Therapeutic Rationale

RAS proteins cycle between GDP-bound inactive and GTP-bound active conformations. Growth-factor receptor signaling activates guanine nucleotide exchange factors, promoting GDP–GTP exchange. Active RAS then engages downstream effectors, including RAF and PI3K. GTPase-activating proteins normally promote conversion back to RAS-GDP. Oncogenic mutations can impair this regulatory cycle and maintain signaling. In PDAC, KRAS alterations are dominant, with G12D, G12V, and G12R among clinically relevant variants. A multi-selective RAS (ON) strategy is therefore biologically attractive because it does not depend on a single mutation such as KRAS G12C.

Mechanism of Action

Daraxonrasib is a noncovalent RAS (ON) multi-selective inhibitor. It first engages intracellular cyclophilin A (CypA), generating a drug-CypA complex that interacts with active GTP-bound RAS. The resulting three-component complex-CypA-daraxonrasib-RAS (ON)-occupies a composite interface involving RAS switch regions and prevents effective engagement of downstream effector proteins. The pharmacological sequence can be summarized as: daraxonrasib + CypA → binary complex → RAS-GTP binding → tri-complex formation → impaired RAS-effector interaction → reduced downstream signaling → inhibition of RAS-dependent tumor growth.

RAS (ON) Multi-Selectivity

Unlike allele-specific KRAS G12C inhibitors, daraxonrasib was designed to inhibit a broad range of RAS proteins in the active state, including mutant and wild-type RAS. This approach is particularly relevant to tumors such as PDAC in which multiple KRAS variants are encountered. Importantly, broad mechanistic activity should not be equated with established clinical efficacy in every RAS alteration or cancer type; the current FDA-approved indication is metastatic pancreatic adenocarcinoma.

Drug Discovery and Development

Daraxonrasib emerged from a structure-guided medicinal-chemistry program aimed at exploiting the interaction between cyclophilin A and active RAS. The discovery program optimized potency, oral bioavailability, metabolic properties, and broad RAS activity. The compound was subsequently evaluated in early clinical studies and advanced into randomized phase 3 development in metastatic PDAC.

Pharmacodynamics

The intended pharmacodynamic effect is sustained suppression of RAS signaling. Inhibition of RAS–effector interaction reduces signaling through the MAPK pathway and other RAS-dependent networks, ultimately reducing proliferative and survival signals. Pharmacodynamic biomarker studies are important for understanding target engagement, pathway suppression, response, and resistance.

Pharmacokinetics

Daraxonrasib is administered orally once daily. Clinical development established 300 mg once daily as the approved regimen. For a final regulatory submission, pharmacokinetic parameters such as Cmax, AUC, terminal half-life, food effect, metabolizing enzymes/transporters, renal impairment, hepatic impairment, and population-PK estimates should be taken directly from the final U.S. prescribing information rather than inferred from investigational reports.

Clinical Development

Early clinical studies evaluated daraxonrasib in patients with advanced RAS-driven solid tumors and provided evidence of antitumor activity. These data supported subsequent randomized development in metastatic PDAC. The pivotal RASolute 302 study compared daraxonrasib with investigator’s-choice standard chemotherapy in patients with previously treated metastatic PDAC.

RASolute 302 Phase 3 Trial

RASolute 302 was a global, randomized, open-label, phase 3 trial (NCT06625320). A total of 500 patients were randomized 1:1 to daraxonrasib or investigator’s-choice standard-of-care chemotherapy after progression following one prior line of systemic therapy. The trial’s dual primary endpoints were overall survival and progression-free survival in the RAS G12 population. Key secondary endpoints included these outcomes in the overall population, objective response, patient-reported quality of life, and safety. Of the 500 participants, 91.8% had RAS G12 mutations.

Table 2. RASolute 302 Key Outcomes

Outcome Daraxonrasib Chemotherapy Effect
Patients 248 252 Randomized 1:1
Median OS, overall population 13.2 months 6.7 months HR 0.40
Median PFS, overall population 7.2 months 3.6 months HR 0.49
Objective response rate 30% 11% P<0.0001
Grade ≥3 adverse events 61.8% 69.6% Lower with daraxonrasib
Treatment-related discontinuation 1.2% 11.2% Lower with daraxonrasib

Table 3. Key Safety Monitoring Framework

Toxicity/Issue Pharmacist Monitoring Clinical Action
Dermatologic/soft tissue toxicity Rash, dryness, fissures, paronychia Early supportive care; follow label-based dose modification
Stomatitis/oral disorders Oral pain, ulcers, impaired intake Oral hygiene/supportive care; assess severity
Diarrhea Frequency, dehydration, electrolytes Hydration/supportive therapy; dose modification when indicated
GI perforation Severe abdominal pain, tenderness, fever Urgent medical evaluation
ILD/pneumonitis New cough, dyspnea, hypoxemia Prompt evaluation; manage according to prescribing information
Drug interactions CYP3A/P-gp modulators and narrow-therapeutic-index drugs Medication reconciliation and interaction management
Embryo-fetal risk Pregnancy potential and contraception Counsel and follow current label recommendations

Evidence note: Regulatory and pivotal-trial figures in this manuscript were checked against the FDA approval notice and the 2026 New England Journal of Medicine RASolute 302 publication.

Efficacy Outcomes

In the overall population, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy (HR 0.40; 95% CI 0.30–0.53; P<0.0001). Median progression-free survival was 7.2 versus 3.6 months (HR 0.49; 95% CI 0.38–0.64; P<0.0001). Objective response rate was 30% versus 11% (P<0.0001). In the RAS G12 population, median overall survival was 13.2 versus 6.6 months and median progression-free survival was 7.3 versus 3.5 months, with HRs of 0.40 and 0.45, respectively.

Safety and Adverse Drug Reactions

In RASolute 302, adverse events of grade 3 or higher occurred in 61.8% of patients receiving daraxonrasib and 69.6% receiving chemotherapy. Treatment-related adverse events leading to discontinuation occurred in 1.2% and 11.2%, respectively. Important identified risks include dermatologic and soft-tissue toxicity, stomatitis and oral disorders, diarrhea, gastrointestinal perforation, interstitial lung disease/pneumonitis, and embryo-fetal toxicity.

Dose and Administration

The FDA-approved dosage is 300 mg orally once daily, continued until disease progression or unacceptable toxicity. Dose interruption or modification should follow the current prescribing information when clinically significant toxicity occurs. Patients should receive clear instructions regarding adherence and management of missed doses according to the product label.

Drug- Drug Interactions

Because daraxonrasib is an oral targeted anticancer agent, medication reconciliation is essential. The final prescribing information should be consulted for specific CYP3A and P-glycoprotein interaction recommendations. Pharmacists should screen prescription medicines, OTC products, supplements, and herbal products at treatment initiation and whenever medications change. Particular attention should be paid to strong enzyme inhibitors/inducers and concomitant drugs with narrow therapeutic indices.

Clinical Monitoring

Baseline assessment should include indication verification, medication reconciliation, interaction screening, review of laboratory data, skin and oral assessment, gastrointestinal symptom assessment, nutritional status, and reproductive counseling where applicable. During therapy, monitor adherence, rash and other skin toxicity, stomatitis, diarrhea, abdominal symptoms, respiratory symptoms, hydration, nutrition, and clinically relevant laboratory parameters. New dyspnea or cough warrants prompt assessment for pneumonitis; severe abdominal pain warrants urgent evaluation for gastrointestinal complications.

Clinical Pharmacist’s Role

Clinical pharmacists can contribute throughout the treatment pathway. Key interventions include medication reconciliation, interaction screening, toxicity prevention, supportive-care optimization, adherence counseling, patient education, identification and documentation of adverse drug reactions, and communication with the oncology team. Patient counseling should emphasize once-daily administration, skin care, oral hygiene, diarrhea management, and early reporting of respiratory or severe abdominal symptoms.

Comparison with KRAS G12C Inhibitors

Daraxonrasib differs conceptually from sotorasib and adagrasib. Those agents are mutation-specific KRAS G12C inhibitors that form covalent interactions with KRAS G12C, whereas daraxonrasib is a noncovalent RAS (ON) multi-selective inhibitor that uses CypA to form a tri-complex with active RAS. This broader mechanism is relevant to RAS variants such as G12D and G12V, for which G12C inhibitors are not applicable.

Resistance Mechanisms

Acquired resistance is an important anticipated limitation of targeted RAS inhibition. Potential mechanisms include on-target RAS alterations that reduce drug binding, adaptive upstream signaling, downstream pathway reactivation, activation of parallel pathways, and tumor heterogeneity. Serial molecular profiling and combination strategies may help define and overcome resistance mechanisms.

Combination Strategies and Future Directions

Future development may include combinations with chemotherapy, SHP2 inhibition, MEK/ERK pathway inhibition, immunotherapy, or other synthetic-lethal approaches. Earlier-line metastatic disease, adjuvant therapy, and other RAS-driven cancers such as NSCLC and colorectal cancer are also areas of investigation. These uses remain investigational unless and until supported by regulatory approval.

Pharmacoeconomic Considerations

Economic evaluation should incorporate drug acquisition cost, treatment duration, adverse-event management, hospitalization, outpatient monitoring, quality-adjusted survival, progression-free survival, and overall survival. Oral administration may reduce some infusion burden but does not necessarily imply lower total treatment cost. Real-world cost-effectiveness data will be important as use expands.

Current Regulatory Status

The U.S. FDA approved daraxonrasib (Rasonque) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multi-agent systemic therapy. The approved dose is 300 mg orally once daily until disease progression or unacceptable toxicity. FDA review was conducted under project Orbis and the real-time oncology review framework.

Strengths and Limitations

Strengths include a novel active-state RAS mechanism, broad RAS selectivity, oral administration, and robust phase 3 evidence demonstrating clinically meaningful survival benefit. Limitations include clinically relevant toxicity, the possibility of acquired resistance, limited long-term post marketing experience because of the recent approval, and the fact that efficacy demonstrated in metastatic PDAC should not automatically be extrapolated to every RAS-mutated malignancy.

Conclusion

Daraxonrasib is a landmark RAS-targeted therapy that validates a noncovalent, CypA-mediated tri-complex approach to active-state RAS inhibition. In previously treated metastatic PDAC, the RASolute 302 trial demonstrated substantial improvements in overall survival, progression-free survival, and objective response compared with standard chemotherapy. FDA approval in August 2026 establishes daraxonrasib as a new treatment option for metastatic pancreatic adenocarcinoma and provides an important proof of concept for multi-selective RAS (ON) inhibition. Appropriate patient selection, medication review, toxicity monitoring, interaction assessment, and pharmacist-led counseling will be central to safe and effective use.

Conflicts of Interest: The authors declare no conflict of interest.

References

  1. U.S. Food and Drug Administration. FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma. August 26, 2026.
  2. O’Reilly EM, Wainberg ZA, Wolpin BM, et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Adenocarcinoma. N Engl J Med. 2026;395(4):325-337. doi:10.1056/NEJMoa2605555.
  3. Wolpin BM, et al. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. N Engl J Med. 2026. doi:10.1056/NEJMoa2505783.
  4. Cregg J, Edwards AV, Freilich R, et al. Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. J Med Chem. 2025;68(6):6064-6083. doi: 10.1021/acs.jmedchem.4c02314.
  5. ClinicalTrials.gov. NCT06625320. Phase 3 Study of Daraxonrasib (RMC-6236) in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma.
  6. Revolution Medicines. Daraxonrasib clinical development program and RAS(ON) inhibitor platform. 2026.
  7. National Cancer Institute. Daraxonrasib. NCI Drug Dictionary.
  8. U.S. Food and Drug Administration. Oncology approval information for daraxonrasib/Rasonque. 2026.
Kauvery Hospital